In recent years, the peptide industry has undergone rapid transformation.

From an early-stage research-focused niche to the large-scale global commercialization of GLP-1 therapies such as semaglutide and tirzepatide, peptides have evolved into one of the fastest-growing segments in the biopharmaceutical industry.

As global demand continues to expand, a more fundamental shift is also taking place: competition is increasingly centered not on molecular innovation itself, but on the ability to achieve stable, large-scale, and low-risk industrial manufacturing.

Against this backdrop, global peptide industrialization is accelerating, and China’s manufacturing advantages are gradually taking shape.

HongKong DengYueMed will analyze China’s competitive strengths in global peptide manufacturing from four core capability dimensions.

Global Acceleration of Peptide Industrialization

With the rapid global expansion of GLP-1 therapies, the peptide industry is transitioning from a research-driven stage to an industrialization-driven stage.

The essence of this shift is not merely demand growth, but a forced upgrade of manufacturing systems.

On one hand, the continued commercialization of blockbuster drugs such as semaglutide and tirzepatide has driven exponential growth in global demand for peptide APIs, placing increasing pressure on the supply side.

On the other hand, peptides are inherently characterized by complex structures, long synthesis pathways, and challenging purification processes, making them fundamentally unsuitable for traditional small-molecule-scale manufacturing logic.

As a result, the industry is undergoing a key transformation: competition is shifting from standalone R&D capabilities toward a system-level competition centered on CDMO infrastructure, industrial-scale manufacturing capabilities, and supply chain stability.

In this process, peptide manufacturing is no longer just a chemical synthesis challenge, but a typical industrial engineering problem involving scale-up capability, raw material systems, production line design, and global supply coordination.

Against this backdrop, China’s systemic capabilities in peptide manufacturing are becoming increasingly prominent, and the country is gradually moving toward a more central position in the global supply chain.

The following will analyze China’s core advantages in peptide manufacturing from four competitive dimensions.

Core Advantage 1: SPPS Engineering Capabilities Have Evolved from Laboratory Research to Industrial-Scale Manufacturing

The core technology behind peptide manufacturing is solid-phase peptide synthesis (SPPS). However, what truly determines industrial competitiveness is not simply whether a peptide can be synthesized, but whether it can be consistently scaled up for commercial production.

The development of China’s peptide CDMO sector essentially represents a transition from laboratory capability to industrial manufacturing capability.

On one hand, Chinese manufacturers are now able to achieve stable scale-up from milligram-level research to kilogram-level and even larger-scale commercial production. This is particularly important in long-chain peptides, where high purity and stable impurity control must be maintained during scale expansion.

On the other hand, manufacturing processes have gradually become more standardized and reusable. Complex peptide sequences no longer rely entirely on individual project experience, but increasingly follow modularized synthesis and purification pathways.

At the same time, the adoption of automated SPPS systems and improvements in multi-project parallel development capabilities have enabled clinical sample production and commercial manufacturing to proceed simultaneously, significantly improving overall delivery efficiency.

Core Advantage 2: A Well-Established Upstream Chemical Supply System Enhances Supply Chain Stability

The stability of the peptide industry depends heavily on the completeness of the upstream chemical supply system, rather than manufacturing capability alone.

China’s advantage in this area lies in the high level of integration already established across its upstream supply chain, mainly reflected in the following aspects:

1.  Amino acids and their derivatives are supplied through a relatively mature local ecosystem, providing stable and continuous access to core raw materials while reducing dependence on external suppliers.

2.  Key coupling reagents have already achieved large-scale domestic production. Core reagents such as HATU and DIC are now widely available in China, improving the stability of critical peptide synthesis processes.

3.  China’s fine chemical industry is highly developed, with relatively complete supporting supply chains for solvents and basic chemical materials, providing a strong foundation for continuous manufacturing operations.

The value of this system goes beyond cost reduction. More importantly, it improves overall supply chain responsiveness, allowing process adjustments, raw material replenishment, and project switching to be completed more efficiently, which is essential for the highly dynamic and fast-iterating nature of peptide manufacturing.

Core Advantage 3: Cost Advantages Are Driven by System Efficiency Rather Than Low Labor Costs Alone

China’s competitiveness in peptide manufacturing cannot simply be attributed to low costs. Instead, it is built upon multiple structural advantages working together.

First, the broader manufacturing ecosystem — including engineering construction, labor resources, and industrial infrastructure — provides lower marginal costs for capacity expansion.

Second, large-scale manufacturing has created significant efficiency gains. As CDMO capacities continue to expand, higher equipment utilization naturally reduces unit production costs, while ongoing process optimization further lowers material loss rates.

In addition, the high level of competition within the industry continuously pushes companies to improve operational efficiency and optimize manufacturing workflows, ultimately creating a structural advantage where both cost control and quality improvement can advance simultaneously.

Core Advantage 4: Rapid Capacity Expansion and Industrial Clusters Strengthen Global Supply Flexibility

One defining characteristic of the peptide industry is the rapid fluctuation in demand, especially during periods of accelerated GLP-1 market expansion, where supply responsiveness becomes critically important.

China’s advantage in this area is mainly reflected in its expansion speed and execution efficiency. Companies are able to complete production line construction and capacity release within relatively short timeframes, while also supporting rapid switching between different peptide projects.

At the same time, regional industrial clusters further strengthen this capability.

The Yangtze River Delta and Pearl River Delta regions have developed highly collaborative ecosystems across equipment supply, analytical testing, and process development, enabling technical expertise to spread and scale quickly throughout the industry.

This structure has allowed China to evolve from being merely a source of manufacturing capacity into an increasingly important center for global supply flexibility in the peptide industry.

Global Peptide Supply Chains Are Being Reshaped, and China’s Role Continues to Expand

As GLP-1 drugs and next-generation peptide therapeutics continue to grow rapidly, global supply chains are shifting from decentralized production models toward more centralized and high-efficiency manufacturing systems.

In this transition, China’s peptide manufacturing sector has evolved from an outsourced production base into a key component of the global core supply system, playing an increasingly important role in commercial supply and long-term capacity support.

For a deeper understanding of this transformation, including differences in production scale, technical capabilities, and customer structures among Chinese peptide companies, readers may also refer to China Peptide API Company Landscape and Capacity Distribution for a more systematic analysis of the industry structure.

Conclusion

Overall, China’s core advantages in global peptide manufacturing stem from four key areas: mature SPPS engineering capabilities, a highly integrated upstream chemical supply system, system-level cost efficiency, and strong rapid-expansion and industrial cluster capabilities.

Together, these factors form China’s structural competitiveness within the global peptide API supply chain and continue to strengthen under the new growth cycle driven by GLP-1 therapies.

As a participant in China’s peptide raw material supply chain, DengYueMed continues to connect high-quality Chinese peptide API resources with global market demand, providing stable, high-quality, and scalable supply solutions.